Revenue

12 Months Ended

Dec. 31, 2022

Revenue from Contract with Customer [Abstract]

Revenue

Revenue

Net Sales by Product

MIMEDX has two classes of products: (1) Advanced Wound Care, or Section 361, products, consisting of its tissue and cord sheet allograft products as well as certain particulate products regulated under Section 361, and (2) Section 351 products, consisting of the Company’s micronized and certain other particulate products. Advanced Wound Care is further disaggregated between the Company’s Tissue/Other and Cord products.

Information regarding the business units responsible for the sale of each of these classes of product can be found in Note 13, Segment Information.

Below is a summary of net sales by each class of product (in thousands):

	Year Ended December 31,
	2022		2021		2020
Advanced Wound Care
Tissue/Other	$	241,992	$	216,418	$	192,566
Cord	23,211		23,599		16,073
Advanced Wound Care	265,203		240,017		208,639
Section 351	2,379		17,610		31,828
Other(1)	259		988		7,767
Total	$	267,841	$	258,615	$	248,234

(1) “Other” includes the Remaining Contracts and other revenue transactions in the indicated period relating to performance obligations settled prior to October 1, 2019, the date at which the Company changed its pattern of revenue recognition. For all practical purposes, the Company is not able to allocate these revenue transactions to different product groups. This revenue is reflected as part of the Wound & Surgical segment.

Net Sales by Site of Service

MIMEDX has three sites of service for its products (1) Hospital settings and wound care clinics, which are stable reimbursement settings in which products are used for surgical applications, (2) Private offices, which generally represents doctors and practitioners with independent operations, and (3) Other, which includes federal facilities, international sales, and other sites of service.

Below is a summary of net sales by site of service (in thousands):

	Year Ended December 31,
	2022		2021		2020
Hospital	$	163,206	$	154,580	$	144,285
Private Office	77,158		$	75,816	$	75,638
Other	27,477		28,219		28,311
Total	$	267,841	$	258,615	$	248,234

Disaggregation of Revenue by Customer

Prior to May 31, 2021, the conclusion of the FDA’s enforcement discretion period, the Company evaluated its revenue on the basis of its two primary distribution channels: (1) direct to customers (healthcare professionals and/or facilities) (“Direct Customers”); and (2) sales through distributors (“Distributors”).

Below is a summary of net sales by each customer type (in thousands):

	Year Ended December 31,
	2022		2021		2020
Direct Customers	$	261,508	$	250,009	$	240,690
Distributors	6,333		8,606		7,544
Total	$	267,841	$	258,615	$	248,234

The Company did not have significant foreign operations or a single external customer from which 10% or more of revenues were derived during the years ended December 31, 2022, 2021, or 2020.